Dr. Altman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
676 N Saint Clair St
Ste 850
Chicago, IL 60611Phone+1 312-695-4125Fax+1 312-695-7814
Education & Training
- McGaw Medical Center of Northwestern UniversityFellowship, Hematology and Medical Oncology, 2004 - 2007
- University of ChicagoResidency, Internal Medicine, 2001 - 2004
- University of Pittsburgh School of MedicineClass of 2001
Certifications & Licensure
- IL State Medical License 2001 - 2026
- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Clinical Trials
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
- Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsUnique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institutionJuehua Gao, Yi Hua Chen, Alain Mina, Jessica K. Altman, Kwang Youn Kim
Human Pathology. 2020-02-21 - 108 citationsAmerican Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adultsMikkael A. Sekeres, Gordon H. Guyatt, Gregory A. Abel, Shabbir M.H. Alibhai, Jessica K. Altman
Blood Advances. 2020-08-11 - 16 citationsPhase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphomaAndrew M. Evens, Jessica K. Altman, Bharat B. Mittal, N. Hou, Alfred Rademaker
Annals of Oncology. 2006-10-06
Journal Articles
- Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLDaniel A Pollyea, Amir T Fathi, Geoffrey L Uy, Robert K Stuart, Mikkael A Sekeres, Courtney D DiNardo, Alice S Mims, Eyal C Attar, Richard M Stone, Hagop M Kantarjian,..., The New England Journal of Medicine
Lectures
- Targeting Treatment According to Molecular Assessment of Acute Myeloid LeukemiaASCO Annual Meeting 2019 - Chicago, IL - 5/31/2019
- MDS + AML MATTER: A Multidisciplinary Approach to Testing and Diagnosis, Evaluation of Risk, and Personalized Treatment Selection60th American Society of Hematology Annual Meeting - 12/1/2018
- Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Tr...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Improving Treatment for Hairy Cell LeukemiaJanuary 11th, 2023
- Study Shows Structural Racism Can Result in Poorer Leukemia OutcomesMarch 7th, 2022
- Expect More Health Plans, Insurers, and Stable Premiums in 2022 as Part of Affordable Care ActAugust 10th, 2021
- Join now to see all
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: